Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;27(3):397-406.
doi: 10.1002/epd2.70012. Epub 2025 Mar 12.

Neonatal/infantile-onset genetic epilepsies: The utility of genetic testing for molecular etiology-specific diagnosis concerning therapeutic implications

Muhittin Ozcan  1 , Seda Kanmaz  2 , Erdem Simsek  2 , Dilara Ece Toprak  2 , Cemile Büsra Olculu  2 , Tugce Ince  2 , Ozlem Yılmaz  2 , Yavuz Atas  2 , Gursel Sen  2 , Ayca Aykut  3 , Asude Durmaz  3 , Hüseyin Onay  3 , Sanem Yılmaz  2 , Hasan Tekgul  2
Affiliations

Neonatal/infantile-onset genetic epilepsies: The utility of genetic testing for molecular etiology-specific diagnosis concerning therapeutic implications

Muhittin Ozcan et al. Epileptic Disord. 2025 Jun.

Abstract

Objective: To evaluate the significance of genetic testing in neonatal- and infantile-onset genetic epilepsies (NIGEP) for enhanced molecular diagnosis with management implications.

Methods: A single-center cohort of 128 patients with NIGEP (aged 0-36 months) from 2010 to 2022 was retrospectively assessed. The diagnostic utility of genetic testing, including next-generation sequencing (NGS) and chromosome-based approaches, was surveyed to determine their impact on antiseizure medication adjustments and precision medicine.

Results: Molecular diagnoses were obtained in 110 patients (85.9%) using NGS and in 18 (14.1%) using chromosome-based tests, identifying pathogenic genetic variants. The most frequently identified genetic variants were SCN1A (12.2%), TSC1-2 (12.2%), ALDH7A1 (10.2%), CDKL5 (10.2%), KCNQ2 (10%), and STXBP1 (6.1%) in the neonatal- and early infantile-onset group (0-3 months); SCN1A (25.3%), TSC1-2 (11.3%), UBE3A (10.1%), and STXBP1 (3.7%) in the late infantile-onset group (>3 months). A molecular-etiopathogenetic categorization was based on the genes encoding ion channels and transporters (n = 40, 31.2%), proteins with cell functions (n = 42, 32.8%), proteins and enzymes in metabolic pathways (n = 36, 28.2%), and an undefined group (n = 10, 7.8%). The molecular-genetic diagnostic provided a potential treatment yield of 61.7% (79/128) for targeted therapy with antiseizure modification/precision therapy. The targeted therapy group demonstrated lower rates of drug-resistant epilepsy (46.7%) and developmental and epileptic encephalopathy (82.3%).

Significance: The current study emphasizes the value of genetic testing in enabling the management of targeted therapies in the context of antiseizure medication modifications or precision therapy implications in the presented NIGEP cohort, contributing to more favorable outcomes.

Keywords: diagnostic utility; infantile‐onset genetic epilepsies; neonatal‐onset genetic epilepsies; next‐generation sequencing; precision therapy.

PubMed Disclaimer

References

REFERENCES

    1. Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63:1349–1397.
    1. Heyne HO, Artomov M, Battke F, Bianchini C, Smith DR, Liebmann N, et al. Targeted gene sequencing in 6994 individuals with neurodevelopmental disorder with epilepsy. Genet Med. 2019;21(11):2496–2503. https://doi.org/10.1038/s41436‐019‐0531‐0
    1. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501(7466):217–221. https://doi.org/10.1038/nature12439
    1. Scheffer IE, Bennett CA, Gill D, de Silva MG, Boggs K, Marum J, et al. Exome sequencing for patients with developmental and epileptic encephalopathies in clinical practice. Dev Med Child Neurol. 2023;65(1):50–57.
    1. Bayat A, Bayat M, Rubboli G, Møller RS. Epilepsy syndromes in the first year of life and usefulness of genetic testing for precision therapy. Genes (Basel). 2021;12(7):1051. https://doi.org/10.3390/genes12071051

Substances